On May 11, the U.S. Department of Health and Human Services (HHS) ended its COVID-19 Public Health Emergency (PHE) declaration that had been in effect since January 2020. Along with it, a long list of pandemic-era policy changes and regulatory waivers that had been in place for more than three years expired. However, not all pandemic-era policies ended on May 11. As a result of recent actions by either Congress or HHS, several key policies that were originally tied to the emergency declaration have continued. For many industry stakeholders, the most important of such policies is the ability of healthcare providers to prescribe controlled substances via telehealth. Prior to the PHE, telehealth prescribing of controlled substances was only permitted following an in-person patient visit (per the Ryan Haight Online Pharmacy Consumer Protection Act of 2008). During the PHE, that in-person requirement was lifted, allowing for telehealth prescribing of medically necessary controlled substances without an in-person visit (assuming all other federal and state legal requirements for issuing a prescription were met). As a result, many healthcare providers and patients (especially in the behavioral health and substance use recovery specialties) grew accustomed to this practice. In parallel, HHS and the U.S. Drug Enforcement Administration (DEA) came to recognize the benefits of it, so much so that on February 24, the DEA released two proposed rules that would have allowed providers in certain situations to continue to prescribe certain controlled substances via telehealth after May 11.